Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Conditions

• Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC
• EGFR Mutation-negative and ALK Rearrangement-negative
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2
• No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
• PD-L1 Positive, as Determined by a Validated Assay

Interventions

• DRUG: Ivonescimab Injection

Sponsor

Guangdong Association of Clinical Trials